Subscribe to RSS
Download PDF
DOI: 10.1055/s-0045-1809302
CD138-Negative Extra-oral Plasmablastic Lymphoma in an Immuno-competent Patient—Diagnostic Challenge: A Case Report and Review of Literature
Funding None.
Abstract
Plasmablastic lymphoma (PBL) is an aggressive lymphoid neoplasm, classified as a distinct entity in 2017 World Health Organization classification. These are generally associated with immunodeficiency states especially in human immunodeficiency virus (HIV)-infected individuals with oral cavity as the most common site. PBL cases have morphologic and immunophenotypic features lying within the spectrum of large B-cell lymphoma and multiple myeloma with tumor cells displaying plasmacytic immunohistochemical markers; CD38, CD138, and IRF4/MUM1. Diagnosis poses a challenge when CD138 immunohistochemistry (IHC) is negative and the tumor presents at extra-oral sites in an immunocompetent patient.
We report an unusual case of CD138-negative PBL in an immunocompetent patient involving the gastrointestinal tract with extensive review of literature. The present case was a 51-year-old man who presented with abdominal fullness and pain. Imaging and endoscopy showed an extensive ulcero-proliferative lesion in the intestines involving the ascending colon to rectum and appendix. Small biopsy from the ascending colon was mistaken for an undifferentiated high-grade malignant neoplasm of uncertain lineage on limited IHC panel (negative CD45, Pan cytokeratin, Synaptophysin, CD20, CD3, but high Ki67).
After an extensive workup on resected hemicolectomy specimen combined with various hematological parameters, the final diagnosis of CD138-negative PBL was made, with three notable features; CD138 negativity, extraoral site, and HIV negativity, leading to delay in diagnosis. Lesson learnt from this case was that PBLs may be CD138-negative that can be missed if not included in the differential diagnosis of tumors with uncertain line of differentiation.
Authors' Contributions
S.K.: literature search, manuscript preparation, manuscript editing and review.
T.V.: concept, literature search.
A.D.: literature search, data acquisition.
N.S.: concept, manuscript review.
A.G.: concept, clinical review with follow-up, manuscript review.
K.R.: data acquisition.
S.K.V.: data acquisition, clinical content.
M.M.G.: concept, design, literature search, manuscript editing, and manuscript review.
Patient's Consent
Consent waiver form uploaded with reason for requesting consent waiver.
Publication History
Article published online:
20 May 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Swerdlow SH, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2017
- 2 Delecluse HJ, Anagnostopoulos I, Dallenbach F. et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89 (04) 1413-1420
- 3 Morscio J, Dierickx D, Nijs J. et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38 (07) 875-886
- 4 Yamada T, Hara T, Goto N, Iwata H, Tsurumi H. Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma. Int J Hematol 2019; 109 (06) 723-730
- 5 Choudhuri J, Pan Z, Yuan J. et al. CD138- Plasmablastic Lymphoma: A Multi-institutional Study and Review of the Literature. Arch Pathol Lab Med 2023; 147 (06) 643-654
- 6 Li JW, Peng HL, Zhou XY, Wang JJ. Plasmablastic lymphoma: current knowledge and future directions. Front Immunol 2024; 15: 1354604
- 7 Li YJ, Li JW, Chen KL. et al. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood Res 2020; 55 (01) 49-56
- 8 Loghavi S, Alayed K, Aladily TN. et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 2015; 8: 65
- 9 Swerdlow SH, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, France: IARC; 2008
- 10 Swerdlow SH, Campo E, Pileri SA. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20) 2375-2390
- 11 Bibas M. Plasmablastic lymphoma. A state-of-the-art review: part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors, and special populations. Mediterr J Hematol Infect Dis 2024; 16 (01) e2024007
- 12 Harmon CM, Smith LB. Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 2016; 140 (10) 1074-1078
- 13 Jafie ESHN, Stein H, Wardiman JW. Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001
- 14 Bibas M. Plasmablastic lymphoma. a state-of-the-art review: part 2-focus on therapy. Mediterr J Hematol Infect Dis 2024; 16 (01) e2024015